EyePoint, Inc. is a clinical-stage biopharmaceutical company developing therapeutic treatments for serious retinal diseases, particularly wet age-related macular degeneration and diabetic macular edema. The company's core technology platform, Durasert E, is a proprietary bioerodible system that delivers drugs directly into the eye over extended periods through sustained-release intraocular injections, reducing the treatment burden of frequent monthly injections required by current therapies. EyePoint's lead product, DURAVYU, combines a selective tyrosine kinase inhibitor with the Durasert E platform to address both vascular and inflammatory pathways in retinal disease; the company also generates royalty revenue from out-licensed approved products and receives milestone payments from development partnerships, while its manufacturing operations support both internal development and future commercialization.